Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability

Journal of Neuroimmunology

Volumn 122, Issue 1-2, 2002, Pages 132-139

  Semra, Y K ^a   Seidi, O A ^a   Sharief, M K ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

Actin; Cerebrospinal fluid; Multiple sclerosis; Neurofilament; Tubulin

Indexed keywords

ACTIN; BIOCHEMICAL MARKER; CYTOSKELETON PROTEIN; NEUROFILAMENT PROTEIN; TUBULIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISABILITY; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NERVE FIBER; NERVE FIBER DEGENERATION; NEUROFILAMENT; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN SECRETION; RECURRENT DISEASE;

ACTINS; AXONS; CYTOSKELETON; DISABILITY EVALUATION; DISEASE PROGRESSION; HUMANS; MULTIPLE SCLEROSIS; NEUROFILAMENT PROTEINS; PREDICTIVE VALUE OF TESTS; TUBULIN;

EID: 0036145606     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(01)00455-6     Document Type: Article

References (45)

1. Axonal damage induced by cerebrospinal fluid from patients with relapsing-remitting multiple sclerosis
2. Multiple sclerosis-emerging concepts of disease pathogenesis
3. Magnetic resonance spectroscopy: Imaging axonal damage in MS
4. Molecular pathogenesis of multiple sclerosis
5. Perturbation of myelination by activation of distinct signaling pathways: An in vitro study in a myelinating culture derived from fetal rat brain
6. A real-time insight into disease progression and the role of axonal injury in multiple sclerosis
7. Quantitation of proteoglycans as glycosaminoglycans in biological fluids using an alcian blue dot blot analysis
8. CSF tau levels increase with age in healthy individuals
9. Appearance of tuberculoma during the course of TB meningitis
10. Binding of Gelsolin, a secretory protein, to amyloid beta-protein
11. Antibodies to tubulin and microtubule-associated proteins: A study in diabetes-mellitus, systemic lupus erythematosus, and rheumtoid arthritis
12. Astroglial and neuronal proteins in cerebrospinal fluid as markers of CNS involvement in Lyme neuroborreliosis
13. The actin cytoskeleton and neurotransmitter release: An overview
14. Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics
15. Pathogenesis of two axonopathies does not require axonal neurofilaments
16. Tubulin isoforms are differently expressed in developing and mature neurons: A study on the cerebral cortex of newborn and adult rats
17. Clinical manifestations and therapeutic approach in neurosarcoidosis
18. The cytoskeleton and disease: Genetic disorders of intermediate filaments
19. Increased cerebrospinal fluid ganglioside GM1 concentrations indicating neuronal involvement in all stages of HIV-1 infection
20. Quantitative analysis of polymerase chain reaction products by dot blot
21. Evaluation of tumor marker S-100 in cerebrospinal fluid from subjects with nonischemic brain pathologies
22. Increased cerebrospinal fluid tau protein in multiple sclerosis
23. Quantitative and qualitative alterations of neuronal and glial intermediate filaments in rat nervous system after exposure to 2,5-hexanedione
24. Tubulin synthesis and assembly in differentiating neurons
25. IgG production within the central nervous system: A critical review of proposed formulas
26. Neurofilament protein in cerebrospinal fluid: A potential marker of activity in multiple sclerosis
27. Apolipoprotein E, transthyretin and actin in the CSF of Alzheimer's patients: Relation with the senile plaques and cytoskeleton biochemistry
28. In vitro approaches to study actin and microtubule-dependent cell processes
29. Proton magnetic resonance spectroscopy in brain white matter disorders
30. S-100 beta reflects the extent of injury and outcome, whereas neuronal specific enolase is a better indicator of neuroinflammation in patients with severe traumatic brain injury
31. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
32. Searching for a function for nuclear actin
33. Cerebrospinal fluid - Physiology, analysis and interpretation of protein patterns for diagnosis of neurologicalal diseases
34. Neurofilament protein levels in CSF are increased in dementia
35. Neurofilament is an autoantigenic determinant in myasthenia gravis
36. Serum and cerebrospinal fluid biochemical markers of ALS
37. Axonal degeneration in the pathogenesis of multiple sclerosis
38. Intrathecal production of IgG antibodies to neurofilament-light (NF-L) is elevated in patients with primary and secondary progressive multiple sclerosis
39. A longitudinal study of brain atrophy in relapsing multiple sclerosis
40. Tau protein in cerebrospinal fluid (CSF): A blood-CSF barrier related evaluation in patients with various neurologicalal diseases
41. Gangliosides and sulfatide in cerebrospinal fluid in leukoaraiosis
42. Pathogenesis of tissue injury in MS lesions
43. CSF neurofilament and glial fibrillary acidic protein in normal pressure hydrocephalus
44. Neurofilaments consist of distinct populations that can be distinguished by C-terminal phosphorylation, bundling, and axonal transport rate in growing axonal neurites
45. Axonal cytoskeleton changes in experimental optic neuritis